cagrilintide + semaglutide Blend (Research) Cagrilintide is an amylin analogue

FDA labeling for GLP-1 weight management generally covers adults 18 and older with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or sleep apnea

Compared to a placebo group, the semaglutide group consumed significantly less food during all meals, with a 24% reduced caloric intake over the study period (2)

Functionality and quality remain consistent

The marketing strategy for these medications has therefore been no less egregious and harmful than that of ultra processed food manufacturers

This includes checking your heart health, blood sugar, or liver function